# Real‐World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy‐Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study

## TL;DR

This study shows that trilaciclib helps prevent blood cell loss in esophageal cancer patients undergoing chemoradiotherapy, with no major safety issues.

## Contribution

This is the first real-world evaluation of trilaciclib for preventing myelosuppression in esophageal cancer patients receiving chemoradiotherapy.

## Key findings

- Trilaciclib significantly improved blood cell levels and reduced severe neutropenia and leukopenia.
- There was no febrile neutropenia in the trilaciclib group.
- Survival rates and non-hematological toxicity were similar between groups.

## Abstract

Chemoradiotherapy‐induced myelosuppression (CIM) is the most common adverse event of esophageal cancer treatment, often necessitating reductions or delays in chemotherapy. Current treatments target specific blood cells, causing adverse effects. Trilaciclib, a novel CDK4/6 inhibitor with myeloprotective effects, has not yet been evaluated for its use in esophageal cancer treatment. We aimed to investigate the efficacy and safety of trilaciclib in preventing CIM.

Clinical data were retrospectively collected from 203 patients with esophageal cancer who underwent concurrent radiotherapy at the Department of Radiotherapy of Jiangsu Province People's Hospital between January 2022 and January 2024. Patients were divided into the trilaciclib group (34 patients) and control group (169 patients). Propensity score matching (PSM) was performed to balance the baseline characteristics, and the incidence of myelosuppression and adverse events was compared.

Following PSM, 34 patients were included in each group, with no significant differences in baseline characteristics. The trilaciclib group exhibited significantly higher leukocyte, neutrophil, hemoglobin, and platelet levels (p < 0.05). The trilaciclib group exhibited a lower incidence of grade III–IV neutropenia and leukopenia, and none developed febrile neutropenia. Objective remission and disease control rates were comparable between the groups, with 1‐year overall survival and progression‐free survival rates of 82.0% and 73.4% in the trilaciclib group and 78.9% and 72.7% in the control group (not significant). The incidence of non‐hematological toxic events was similar between the groups (p > 0.05).

Trilaciclib prevented myelosuppression in patients with esophageal cancer undergoing concurrent chemoradiotherapy, demonstrating good safety and efficacy.